315 related articles for article (PubMed ID: 34093863)
1. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
2. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
5. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
6. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
7. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma.
Song H; Huang P; Niu J; Shi G; Zhang C; Kong D; Wang W
Biomaterials; 2018 Mar; 159():119-129. PubMed ID: 29324304
[TBL] [Abstract][Full Text] [Related]
8. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
9. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
10. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
[TBL] [Abstract][Full Text] [Related]
11. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.
Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL
Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795
[TBL] [Abstract][Full Text] [Related]
12. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
Front Immunol; 2018; 9():1997. PubMed ID: 30237798
[TBL] [Abstract][Full Text] [Related]
14. A Novel
Zhang L; Du J; Song Q; Zhang C; Wu X
J Immunol Res; 2022; 2022():1178874. PubMed ID: 35155685
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY
Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797
[TBL] [Abstract][Full Text] [Related]
17. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
18. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]